Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 20/20 | 1.00 |
| ▸ | FLT3 | P36888 | 3/20 | 0.83 |
| ▸ | IKBKE | Q14164 | 3/20 | 0.83 |
| ▸ | RPS6KA6 | Q9UK32 | 3/20 | 0.83 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.83 |
| ▸ | CDK9 | P50750 | 2/20 | 0.83 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.82 |
| ▸ | ULK1 | O75385 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19005341 | 0.91 | TBK1 (1.00) | TBK1FLT3IKBKERPS6KA6CCNT1 | |
| SCHEMBL19005314 | 0.90 | TBK1 (1.00) | TBK1FLT3IKBKERPS6KA6CCNT1 | |
| SCHEMBL19004983 | 0.90 | TBK1 (0.85) | TBK1FLT3IKBKERPS6KA6CCNT1 | |
| SCHEMBL18985876 | 0.90 | TBK1 (1.00) | TBK1FLT3IKBKERPS6KA6CCNT1 | |
| SCHEMBL18985264 | 0.90 | TBK1 (1.00) | TBK1FLT3IKBKERPS6KA6CCNT1 | |
| SCHEMBL19005454 | 0.89 | TBK1 (1.00) | TBK1FLT3IKBKERPS6KA6CCNT1 | |
| SCHEMBL18985439 | 0.89 | TBK1 (1.00) | TBK1FLT3IKBKERPS6KA6CCNT1 | |
| SCHEMBL18985717 | 0.89 | TBK1 (1.00) | TBK1FLT3IKBKERPS6KA6CCNT1 | |
| SCHEMBL18985399 | 0.89 | TBK1 (1.00) | TBK1FLT3IKBKERPS6KA6CCNT1 | |
| SCHEMBL18985885 | 0.89 | TBK1 (1.00) | TBK1FLT3IKBKERPS6KA6CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190047980-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-02-14 | — | — | US | claimed |
| EP-3390387-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | Bayer Pharma Aktiengesellschaft (DE) | 2018-10-24 | — | — | EP | claimed |
| WO-2017102091-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-22 | — | — | WO | claimed |
| EP-3390387-B1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | Bayer Pharma AG (DE) | 2021-11-17 | — | — | EP | disclosed |
| US-10894784-B2 | Heteroarylbenzimidazole compounds | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-01-19 | — | — | US | disclosed |
| US-10894784-B2 | Heteroarylbenzimidazole compounds | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-01-19 | — | — | US | disclosed |
| US-20190047980-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-02-14 | — | — | US | disclosed |
| US-20190047980-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-02-14 | — | — | US | disclosed |
| EP-3390387-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | Bayer Pharma Aktiengesellschaft (DE) | 2018-10-24 | — | — | EP | disclosed |
| WO-2017102091-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-22 | — | — | WO | disclosed |
| WO-2017102091-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190047980-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | CCNI, CCNT2, CDK2 | TBK1 1468/4885FLT3 438/4885IKBKE 87/4885 |
| US-10894784-B2 | Heteroarylbenzimidazole compounds | CCNI, CCNT2, CDK2 | TBK1 1468/4885FLT3 438/4885IKBKE 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.